These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32147777)

  • 81. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

  • 83. CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.
    Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Lenz GS; de Oliveira FH; Wink MR; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1177-1182. PubMed ID: 32417936
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.
    Campderá M; Palacios N; Aller J; Magallón R; Martín P; Saucedo G; Lilienfeld H; Estrada J
    Pituitary; 2016 Apr; 19(2):158-66. PubMed ID: 26586560
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: a case report of early identification and management.
    Zhong C; Yin S; Zhou P; Jiang S
    Turk Neurosurg; 2014; 24(6):963-6. PubMed ID: 25448217
    [TBL] [Abstract][Full Text] [Related]  

  • 86. First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma.
    Allen BG; Bodeker KL; Smith MC; Monga V; Sandhu S; Hohl R; Carlisle T; Brown H; Hollenbeck N; Vollstedt S; Greenlee JD; Howard MA; Mapuskar KA; Seyedin SN; Caster JM; Jones KA; Cullen JJ; Berg D; Wagner BA; Buettner GR; TenNapel MJ; Smith BJ; Spitz DR; Buatti JM
    Clin Cancer Res; 2019 Nov; 25(22):6590-6597. PubMed ID: 31427282
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
    Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
    Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
    BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.
    Burman P; Trouillas J; Losa M; McCormack A; Petersenn S; Popovic V; Theodoropoulou M; Raverot G; Dekkers OM;
    Eur J Endocrinol; 2022 Oct; 187(4):593-605. PubMed ID: 36018781
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Radiation techniques in aggressive pituitary tumours and carcinomas.
    Castinetti F
    Rev Endocr Metab Disord; 2020 Jun; 21(2):287-292. PubMed ID: 32064542
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Medical Therapy of Aggressive Pituitary Tumors.
    Petersenn S
    Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):186-193. PubMed ID: 33690871
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Temozolomide for aggressive pituitary tumors:-A literature review.
    Hui-Zheng H; Lei L
    Asian J Surg; 2024 Feb; 47(2):1300-1301. PubMed ID: 38030489
    [No Abstract]   [Full Text] [Related]  

  • 93. Aggressive pituitary tumours and pituitary carcinomas.
    Raverot G; Ilie MD; Lasolle H; Amodru V; Trouillas J; Castinetti F; Brue T
    Nat Rev Endocrinol; 2021 Nov; 17(11):671-684. PubMed ID: 34493834
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Targeted systemic and peptide radio-ligand therapy for aggressive pituitary tumors and carcinomas.
    Petersenn S; Heaney AP
    Rev Endocr Metab Disord; 2020 Jun; 21(2):277-286. PubMed ID: 32415583
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Long-Term Use of Temozolomide as Safe and Effective Therapy for an Aggressive Corticotroph Adenoma in a Very Old Patient.
    Decaroli MC; Ansaloni A; Monzani ML; Losa M; Zunarelli E; Rochira V; Madeo B
    J Endocr Soc; 2021 Aug; 5(8):bvab065. PubMed ID: 34195524
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.
    Burman P; Casar-Borota O; Perez-Rivas LG; Dekkers OM
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1585-1601. PubMed ID: 36856733
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?-that is the question.
    Trouillas J; Burman P; Losa M; McCormack A; Petersenn S; Popovic V; Theodoropoulou M; Dekkers OM; Raverot G
    Eur J Endocrinol; 2023 Apr; 188(4):C5-C8. PubMed ID: 36952293
    [No Abstract]   [Full Text] [Related]  

  • 98. Aggressive pituitary tumors and carcinomas: medical treatment beyond temozolomide.
    DE Alcubierre D; Carretti AL; Ducray F; Jouanneau E; Raverot G; Ilie MD
    Minerva Endocrinol (Torino); 2024 Jan; ():. PubMed ID: 38240681
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Clinical review: Pituitary carcinoma: difficult diagnosis and treatment.
    Heaney AP
    J Clin Endocrinol Metab; 2011 Dec; 96(12):3649-60. PubMed ID: 21956419
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Pituitary carcinoma as a rare cause of liver metastases successfully treated with temozolomide.
    Stelmachowska-Banaś M; Maksymowicz M; Kolasińska-Ćwikła A; Zieliński G; Korbonits M; Zgliczyński W
    Pol Arch Intern Med; 2022 Mar; 132(3):. PubMed ID: 34935323
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.